The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective
The VITA-FAST tokens have been met with overwhelming interest
Supply readiness follows months of manufacturing to ensure timely and ample supply
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
The development and deployment of effective vaccines can help to mitigate the impact of pandemics, and we must prioritize research efforts to achieve this objective
Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Subscribe To Our Newsletter & Stay Updated
